Skip to main content
ETON
NASDAQ Life Sciences

Eton Pharmaceuticals Announces Planned CFO Succession, Appointing Experienced Executive Judith Matthews

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$26.77
Mkt Cap
$735.863M
52W Low
$12.25
52W High
$27.285
52W Position info
119% above low
Off High info
1.9% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ETON has more than doubled off its 52-week low of $12.25.

Summary

Eton Pharmaceuticals announced a planned CFO transition, with Judith Matthews, an experienced pharmaceutical finance executive, set to take over from James Gruber on June 1, 2026.


Key Events · Executive and Board Changes · ETON

  • New CFO Appointed

    Judith Matthews has been appointed Executive Vice President, Accounting and Finance, and will assume the role of Chief Financial Officer effective June 1, 2026.

  • Planned Succession

    Current CFO James Gruber will step down on May 31, 2026, and will enter into a six-month consulting agreement to ensure a seamless transition.

  • Experienced Executive Joins

    Ms. Matthews brings over 25 years of finance leadership experience, including prior CFO roles at Iterum Therapeutics plc and Vice President of Finance at Durata Therapeutics.

  • Compensation Package

    Ms. Matthews' compensation includes an annual base salary of $440,000 and a one-time option to purchase 37,000 shares of common stock.


Analysis · ETON · Life Sciences

Eton Pharmaceuticals has announced a planned and orderly transition in its Chief Financial Officer role. The appointment of Judith Matthews, an executive with over 25 years of finance leadership experience in the pharmaceutical and biotechnology sectors, signals a focus on strengthening financial leadership during a period of growth. The outgoing CFO, James Gruber, will remain through May 31, 2026, and then serve as a consultant, ensuring a smooth handover. This structured succession plan, coupled with the new CFO's extensive background, is a positive development for the company's operational continuity and strategic financial management.

At the time of this filing, ETON was trading at $26.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $735.9M. The 52-week trading range was $12.25 to $27.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ETON - Latest Insights

ETON
Jul 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $47.73
Real-time Price: $47.44 info
Change: -$0.2932 (-0.61%) info
Market Cap: $1.299B info
ETON
Jul 07, 2026, 6:29 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $37.74
Real-time Price: $47.44 info
Change: +$9.70 (+26%) info
Market Cap: $1.299B info
ETON
Jun 26, 2026, 4:14 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $35.70
Real-time Price: $47.44 info
Change: +$11.74 (+33%) info
Market Cap: $1.299B info
ETON
Jun 17, 2026, 5:08 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $32.76
Real-time Price: $47.44 info
Change: +$14.68 (+45%) info
Market Cap: $1.299B info
ETON
May 29, 2026, 4:16 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $30.45
Real-time Price: $47.44 info
Change: +$16.99 (+56%) info
Market Cap: $1.299B info